GSK and Innoviva begin Phase III Captain study of triple combination therapy to treat asthma

GlaxoSmithKline (GSK) and Innoviva have initiated a Phase III Captain study of a triple combination therapy consisting of fluticasone furoate / umeclidinium / vilanterol (FF/UMEC/VI) compared to dual combination therapy of Relvar / Breo (FF/VI) to tr …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Asthma | Flonase | Study